These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36628321)

  • 1. Disability weights for castration-resistant prostate cancer: an empirical investigation.
    Borsoi L; Ciani O; Vivo R; Russo GI; Scarcia M; De Fino C; Beccaglia P; Luccarini I
    Glob Reg Health Technol Assess; 2022; 9():146-154. PubMed ID: 36628321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
    Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
    Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
    Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model.
    Scher HI; Solo K; Valant J; Todd MB; Mehra M
    PLoS One; 2015; 10(10):e0139440. PubMed ID: 26460686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
    Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
    J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy.
    Borsoi L; Ciani O; Fornarini G; Oderda M; Sciarra A; Vetrini D; Luccarini I
    Int J Technol Assess Health Care; 2023 Jan; 39(1):e2. PubMed ID: 36606465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
    Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
    Freedland SJ; Pilon D; Bhak RH; Lefebvre P; Li S; Young-Xu Y
    Urol Oncol; 2020 Dec; 38(12):930.e13-930.e21. PubMed ID: 32739230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
    Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
    Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
    Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
    Verry C; Vincendeau S; Massetti M; Blachier M; Vimont A; Bazil ML; Bernardini P; Pettré S; Timsit MO
    Target Oncol; 2022 Jul; 17(4):441-451. PubMed ID: 35841526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer.
    Gleicher S; Porter BA; Nath D; Li G; Khanna R; Goldberg H; Kortylewski M; Bratslavsky G; Kotula L
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
    Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
    Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
    [No Abstract]   [Full Text] [Related]  

  • 16. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
    Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
    Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
    Rozet F; Roumeguère T; Spahn M; Beyersdorff D; Hammerer P
    World J Urol; 2016 Nov; 34(11):1505-1513. PubMed ID: 26988552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
    Crawford ED; Andriole G; Freedland SJ; Garnick M; Gomella LG; Henderson J; Higano CT; Kader AK; Kane C; Keane TE; Koo PJ; Petrylak DP; Reiter RE; Slovin SF; Yu EY
    Can J Urol; 2020 Oct; 27(5):10352-10362. PubMed ID: 33049187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
    Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
    J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.